Subscribe to our Newsletters !!
Climate change is very disruptive to the Amazon ra
By 2024, there are certain things you need to do i
Insects that are given more attention and reverenc
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Perkin Elmer a US based multinational company mostly involed in the business of Human and Environmental Health, has launched its NeoBase 2 non-derivatized tandem mass spectrometry (MS/MS) kit, which recently obtained the CE mark. The kit analyzes newborn heel prick blood samples dried on filter paper, and is used with a tandem mass spectrometer.
PerkinElmer Inc, Waltham, Mass, has launched its NeoBase 2 non-derivatized tandem mass spectrometry (MS/MS) kit, which recently obtained the CE mark. The in vitro diagnostic (IVD) kit is intended for the semiquantitative measurement and evaluation of acylcarnitine, amino acid, free carnitine lysophospholipid, nucleoside, and succinylacetone concentrations. The kit analyzes newborn heel prick blood samples dried on filter paper, and is used with a tandem mass spectrometer.
PerkinElmer Inc, Waltham, Mass, has launched its NeoBase 2 non-derivatized tandem mass spectrometry (MS/MS) kit, which recently obtained the CE mark. The in vitro diagnostic (IVD) kit is intended for the semiquantitative measurement and evaluation of acylcarnitine, amino acid, free carnitine lysophospholipid, nucleoside, and succinylacetone concentrations.
The NeoBase2 MS/MS kit can test for up to 57 analytes, including markers for screening of X-linked adrenoleukodystrophy, the most common peroxisomal disorder. It can also screen for adenosine deaminase severe combined immunodeficiency (ADA-SCID), which is caused by a deficiency of the enzyme ADA and is the second most common SCID.
Linh Hoang, MD, PhD, vice president for neonatal screening at PerkinElmer, Says, “As the industry leader in mass spectrometry-based newborn screening, we continue to evolve our technologies to meet the needs of laboratories worldwide,especially as more countries mandate certain metabolic tests such as those for SCIDs and peroxisomal disorders,”
“As these labs face pressure to screen for more disorders in less time and with limited resources, they are seeking advanced technology to expand their MS/MS testing capabilities.”
For more information:Click here
